0000000000018273

AUTHOR

Monique Bertrand

showing 2 related works from this author

Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of front-line carboplatin/paclitaxel (CP) ± bevacizumab (BEV)…

2015

5548 Background: In ICON7, progression-free survival (PFS) was significantly improved in patients (pts) receiving BEV with front-line CP and continued as a single agent [Perren 2011] but no overall...

OncologyCancer Researchmedicine.medical_specialtyBevacizumabbusiness.industrydigestive oral and skin physiologyFront lineDiseasemedicine.diseaseCarboplatin/paclitaxelSurgeryOncologyInternal medicineMedicineSingle agentIn patientStage (cooking)businessOvarian cancermedicine.drugJournal of Clinical Oncology
researchProduct

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab …

2018

Objective In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease. Methods Patients with stage IIB–IV or high-risk (grade 3/clear-cell) stage I–IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5 mg/kg every 3 weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc ex…

0301 basic medicineOncologymedicine.medical_specialtyNeoplasm ResidualPaclitaxelBevacizumabmedicine.medical_treatmentPopulationArticleCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansCytoreductive surgeryStage (cooking)educationNeoplasm StagingOvarian NeoplasmsChemotherapyeducation.field_of_studybusiness.industryHazard ratioObstetrics and GynecologyResidual diseasemedicine.diseaseCarboplatinBevacizumab030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemaleOvarian cancerbusinessmedicine.drug:Ciencias de la Salud::Oncología [Materias Investigacion]
researchProduct